Pediatric Type 1 Diabetes Cases With Exogenous Insulin Antibody Syndrome

Liang Zhang published a retrospective case series on five pediatric patients with type 1 diabetes and exogenous insulin antibody syndrome. The data covers clinical characteristics, lab results, and treatment outcomes for these patients treated between January 2016 and January 2026. It includes longitudinal autoantibody profiles, thyroid function, immune parameters, and cytokines assessed at four time points.

Use Cases

• Analyze the relationship between insulin antibody (IA) titers and glycemic control metrics like Time in Range (TIR) across five patient cases.
• Compare treatment efficacy between ultra-rapid insulin pumps and multiple daily injection regimens using CGM-derived metrics such as TIR and Time Below Range (TBR).
• Model the impact of mycophenolate mofetil (MMF) dosage on IA titer reduction and TIR improvement in a refractory case.
• Examine longitudinal changes in autoantibody profiles, thyroid function, and cytokine levels at four assessment time points for each patient.

Strengths

• Longitudinal data with autoantibody profiles, thyroid function, and cytokines assessed at four time points per patient.
• Includes detailed CGM metrics (TIR, TBR, CV) and specific insulin treatment regimens for each case.
• Dataset is openly licensed under CC-BY-4.0.

Limitations

• Extremely small sample size of only five patient cases, limiting statistical power.
• Data originates from a single center with no control group, introducing potential selection bias.
• Observational, retrospective study design prevents causal inference.

Provenance

Source

Liang Zhang via figshare.

Collection Method

Retrospective case series study of pediatric patients at a single center.

Time Range

Patient data from January 2016 to January 2026.

Freshness

Data last updated March 2026, with patient coverage up to January 2026.